Inhibitors targeting these pathways were tested as single agents, dual combinations, and triple combinations in three NF1-related MPNST cell lines (S462, NF1-08, and NF1-09) to identify potential therapeutic strategies. The gene discussed is NF1; the disease is malignant peripheral nerve sheath tumor.